The two steps in influenza virus RNA replication are (i) the synthesis of template RNAs, i.e., full-length copies of the virion RNAs, and (ii) the copying of these template RNAs into new virion RNAs. We prepared nuclear extracts from infected HeLa cells that catalyzed both template RNA and virion RNA synthesis in vitro in the absence of an added primer. Antibody depletion experiments implicated nucleocapsid protein molecules not associated with nucleocapsids in template RNA synthesis for antitermination at the polyadenylation site used during viral mRNA synthesis. Experiments with the WSN influenza virus temperature-sensitive mutant ts56 containing a defect in the nucleocapsid protein proved that the nucleocapsid protein was indeed required for template RNA synthesis both in vivo and in vitro. Nuclear extracts prepared from mutant virus-infected cells synthesized template RNA at the permissive temperature but not at the nonpermissive temperature, whereas the synthesis of mRNA-size transcripts was not decreased at the nonpermissive temperature. Antibody depletion experiments showed that nucleocapsid protein molecules not associated with nucleocapsids were also required for the copying of template RNA into virion RNA. In contrast to the situation with the synthesis of transcripts complementary to virion RNA, no discrete termination product(s) were made during virion RNA synthesis in vitro in the absence of nucleocapsid protein molecules.
In influenza virus-infected cells, the eight genomic or virion RNAs (vRNAs) are both transcribed into mRNAs and replicated. A great deal is known about the mechanism of synthesis of the viral mRNAs because an in vitro system is available. Nucleocapsids isolated from purified virions catalyze viral mRNA synthesis (16) . This synthesis requires priming by capped RNA fragments that are generated by a viral cap-dependent endonuclease, which cleaves capped RNAs 10 to 13 nucleotides from their 5' ends (3, 12, 16) . The viral mRNA chains are then elongated until a stretch of uridine residues is reached 17 to 22 nucleotides before the 5' ends of the vRNAs are reached, where transcription terminates and poly(A) is added to the mRNAs (8, 17) . The three polymerase (P) proteins (PB1, PB2, PA) that are associated with the nucleocapsids catalyze viral mRNA synthesis. Some of the roles of the P proteins have been elucidated (4, 24, 25) . PB2 recognizes and binds to the cap 1 structure of primer RNAs, and PB1 most likely catalyzes the addition of each nucleotide to the growing viral mRNA chains. The three P proteins move down the elongating viral mRNA chains together as a complex. Although the PA protein is part of this complex, no specific role for PA in viral mRNA synthesis has been found.
In contrast, much less is known about the replication of influenza virus vRNAs. As the first step in replication, an alternative type of transcription of the vRNA is required that results in the production of full-length copies of the vRNAs rather than the production of viral mRNAs. The full-length copies, or template RNAs, are initiated without a primer and are not terminated at the poly(A) site used during mRNA synthesis (8, 9) . In vivo, the switch from viral mRNA to template RNA synthesis requires the synthesis of one or more virus-specific proteins (1, 9) . The second step in replication is the copying of the template RNAs into vRNAs.
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This synthesis also occurs without a primer, since the vRNAs contain 5'-triphosphorylated ends (28) . The copying of template RNAs into vRNAs is an important step of regulation during the early phase of virus infection, since the selective copying of certain template RNAs into their vRNAs determines which viral proteins are preferentially synthesized at early times of infection (8, 20, 21) . As with viral mRNA synthesis (10) , both steps of vRNA replication occur in the nucleus (20) .
To determine the mechanisms of the two steps of replication and the roles of virus-specific proteins in these steps, it is necessary to establish in vitro systems that catalyze both steps of replication. Recently, we prepared infected cell nuclear extracts that were active in the antitermination event that occurs as part of the switch from mRNA to template RNA synthesis (2) . These extracts, however, did not carry out the unprimed initiation of template RNAs. This deficiency was circumvented by providing the dinucleotide ApG as a primer. The viral nucleocapsids isolated from the nuclear extract synthesized only mRNA-sized RNAs and not template RNAs. Antitermination required the action of nuclear factor(s) not associated with the nucleocapsids. Because this factor was removed by depleting the nucleocapsid protein (NP) with anti-NP antibodies bound to protein A-Sepharose (PAS), we concluded that NP molecules which were not associated with nucleocapsids were required for antitermination (2) . Antitermination was controlled not only by the availability of NP but also by the type of initiation. Transcripts initiated with capped RNA primers were not antiterminated in the presence of NP molecules that were active in antiterminating ApG-initiated transcripts (2) .
In the present report, we prepared infected-cell nuclear extracts that catalyzed the synthesis of both template RNA and vRNA in the absence of an added primer. Using a viral temperature-sensitive (ts) mutant, we verified that NP was required for antitermination during template RNA synthesis.
Antibody depletion experiments also indicated that NP molecules not associated with nucleocapsids were required for elongation during vRNA synthesis. In the absence of NP, no discrete termination product(s) was synthesized during vRNA synthesis.
MATERIALS AND METHODS Preparation and fractionation of nuclear extracts from infected cells. Suspension HeLa cells were infected with 10 to 20 PFU of WSN influenza A virus (either the wild type or the ts56 virus mutant) per cell as previously described (11) . At the indicated times after infection, the cells were collected, and nuclear extracts were prepared as described by Dignam et al. (6) . Where indicated, the nuclear extract was centrifuged to yield a supernatant fraction containing nucleocapsid-free viral proteins and a pellet fraction containing nuclear nucleocapsids (2) . To prepare the supernatant, 700 RI of extract was centrifuged at 45,000 rpm for 4.5 10 ,lI of unfractionated nuclear extract, or both 3 RI of the gradient-purified nucleocapsids and 10 [lI of the nuclear supernatant, was added.
Where indicated, 0.4 mM ApG was added.
Analysis of RNA products. (i) Template RNA. Total RNA was extracted and annealed to an excess of a vRNA-sense M13 DNA clone of the NS segment as described previously (2) . After RNase T2 digestion, the RNA-DNA hybrids were collected on nitrocellulose filters. The RNA eluted from these filter-bound hybrids by heating was analyzed by electrophoresis on a 3.5% acrylamide gel containing 8 M urea. (ii) vRNA. The poly(A)-products of in vitro RNA synthesis were annealed to filters containing an mRNA-sense M13 clone. The hybridized RNA was eluted by heating and analyzed by gel electrophoresis.
Antibody depletion experiments. Antibody depletion was carried out as previously described (2) . Briefly, PAS (15 mg) was swollen in 0.5 ml of 50 mM Tris hydrochloride (pH 8)-150 mM NaCl-5 mM EDTA (buffer A) plus 0.1% Nonidet P-40. The specific antiserum (40 to 80 plI) was incubated with the PAS for 18 h at 4°C in Eppendorf tubes. The PAS was spun out, washed three times with buffer A, and then incubated with 80 plI of the nuclear supernatant for 2 h at 4°C. The PAS was spun out, and the resulting supernatant was removed and assayed.
Shift-up experiments with the viral ts mutant ts56. The tsS6 virus mutant was grown and titered as previously described (13, 22) . Monolayer cultures of BHK-21 cells in 75-cm plastic flasks were infected with wild-type or ts56 virus at a multiplicity of 10. The virus was adsorbed for 1 h at 4°C.
After adsorption, 5 ml of prewarmed (33°C) growth medium (reinforced Eagle medium containing 2% calf serum) was added, and the flasks were completely immersed in a water bath maintained at 33°C (permissive temperature). At 3 h postinfection, some flasks were transferred to a water bath maintained at 39.5°C (nonpermissive temperature). At (26), and polyclonal antisera to the NS1 and NS2 proteins were kindly supplied by Peter Palese (7, 27) .
RESULTS
In vitro template RNA synthesis in the absence of a primer. Previously, we prepared infected cell nuclear extracts that catalyzed the synthesis of template RNAs but only in the presence of a primer, the dinucleotide ApG (2). One of our goals was to obtain extracts that synthesized high levels of template RNAs in the absence of ApG. We used an M13 single-stranded DNA to measure the transcripts copied off of one of the vRNAs, NS vRNA (2) . This assay includes a digestion with RNase T2, so that the NS template RNA is about 20 nucleotides larger than the NS1 mRNA and thus has a slower mobility than the NS1 mRNA during gel electrophoresis.
The previous nuclear extracts were obtained from infected HeLa cells at 4 h postinfection (2) . Because the time course of virus-specific RNA synthesis in HeLa cells was delayed as compared with that in other cells, we determined whether nuclear extracts at time points later than 4 h were more active in the absence of ApG. Maximal template RNAsynthesizing activity in the absence of ApG occurred with the extract that was collected at 6 h after infection (Fig. 1) . Much lower activity was present both before and after 6 h. With other 6-h extracts, the ratio of template RNA to mRNA synthesis was higher than that shown in Fig. 1 . In many 6-h extracts, template RNA was the predominant transcription product in the absence of ApG (Fig. 2) Previously, with ApG as the primer, we showed that (i) the nucleocapsids isolated from the nuclear extract synthesized mRNA-size RNA; (ii) the synthesis of template RNA, and hence antitermination, required the addition of the nonnucleocapsid fraction (supernatant fraction) of the extract; and (iii) depletion of NP from this fraction by incubation with PAS containing anti-NP antiserum eliminated antitermination and hence template RNA synthesis (2) . The same results were obtained in the absence of ApG (Fig. 3) . Because anti-NP antiserum depleted antitermination activity from the supernatant, it can be concluded that the nuclear supernatant supplied the NP needed for antitermination (lanes 4 through 7). In contrast, depletion of the supernatant with anti-NS1 or anti-NS2 antiserum did not eliminate template RNA-synthesizing activity (data not shown). It had been shown previously that antibody depletion of the NS1 protein (14, 18) . This experiment showed that vRNA synthesis was drastically inhibited after the shift-up, indicating that the NP was required for vRNA synthesis in vivo. Our goal was to determine whether the NP was also required for template RNA synthesis in vivo. We used a WSN virus ts mutant, ts56, and performed the shift-up at a time at which the rate of template RNA synthesis was still increasing at the permissive temperature, 33°C. In cells infected with ts56 at 33°C, the rate of template RNA synthesis increased until a peak rate was achieved at 4 h postinfection (Fig. 4) . After ts56 extracts, the nuclear extracts from cells infected with wild-type WSN virus synthesized similar amounts of template RNA at 33 and 39.5°C in the absence (lanes 3 and 4) and in the presence (data not shown) of ApG.
In vitro synthesis of virion RNAs. The nucleus is also the site of vRNA synthesis (20) . To determine whether the nuclear extracts synthesized vRNAs, the poly(A)-products of in vitro synthesis were hybridized to filters containing mRNA-sense M13 DNA specific for either M or NS vRNA. The hybridized RNA was eluted and analyzed by gel electrophoresis. Both M and NS vRNAs were synthesized in vitro by nuclear extracts collected at 6, 7, and 8 h postinfection (Fig. 7) . In this particular experiment, the rate of NS vRNA synthesis was highest with the 8-h extract and the rate of M vRNA synthesis was highest with the 6-h extract. However, the results of several experiments indicated that extracts collected at 6, 7, and 8 h were similar in their activities in M and NS vRNA synthesis (data not shown). In contrast (Fig. 1) , template RNA-synthesizing activity decreased markedly with extracts collected later than 6 h postinfection. These results reflect the situation in vivo, 6 7 8 6 7 vRNA synthesis needed nonnucleocapsid NP molecules. A 7-h infected HeLa cell nuclear extract was separated into nucleocapsids and a supernatant fraction as described in the text. RNA synthesis was catalyzed by the unfractionated extract (E), the nucleocapsids alone (P), the supernatant alone (S), or the supernatant plus the nucleocapsids (S+P). Samples of the supernatant were incubated with PAS containing normal rabbit antiserum (S), pooled NP monoclonal antibodies (S-NP), NS1 antiserum (S-NS1), or NS2 antiserum (S-NS2). Each of these supernatant samples was added to the nuclear nucleocapsids to carry out RNA synthesis in vitro (lanes 5, 6, 7, and 8, respectively). The poly(A)-RNA products were analyzed for NS vRNA as described in the text.
where template RNA synthesis shut down soon after its peak rate of synthesis was achieved whereas vRNA synthesis continued at essentially maximal rate (20) .
In contrast to the situation with the synthesis of transcripts complementary to vRNA, the nucleocapsids present in the nuclear pellet fraction did not synthesize a vRNAsense RNA of discrete size in the absence of the supernatant fraction (Fig. 8, lane 2) 
